<DOC>
	<DOC>NCT01186770</DOC>
	<brief_summary>MNTX 3201 is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study in order to evaluate the safety and efficacy of oral MNTX for the treatment of opioid induced constipation in subjects with chronic, non-malignant pain.</brief_summary>
	<brief_title>A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation in Subjects With Chronic, Non-Malignant Pain</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>Key 1. History of chronic nonmalignant pain (originating from a nonmalignant source). 2. Taking oral, transdermal, intravenous, or subcutaneous opioids for chronic nonmalignant pain. 3. No known history of chronic constipation prior to the initiation of opioid therapy. 4. Currently taking laxative therapy and willing to discontinue all laxative therapy prestudy and use only studypermitted rescue laxatives. Key 1. Prior treatment with oral methylnaltrexone. 2. Prior treatment with SC methylnaltrexone within 30 days prestudy. 3. Women who are pregnant, breastfeeding, or plan to become pregnant. 4. Gastrointestinal disorders known to affect bowel transit. 5. Current treatment with partial opioid agonists (e.g., buprenorphine) or combination agonists/antagonists.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Treatment of Opioid-Induced Constipation in Subjects with Chronic, Non-Malignant Pain</keyword>
</DOC>